Ciphergen and Sanofi-Aventis Announces Pharmaceutical Biomarker Research Collaboration
News Feb 09, 2006
Ciphergen has announced that it has extended its existing relationship with sanofi-aventis by signing a collaborative research agreement. The project will concentrate on discovery, validation, and identification of biomarkers for a pre-clinical drug efficacy study in the field of oncology.
Under the terms of the agreement, Ciphergen will analyze samples at one of its Biomarker Discovery Center® laboratories using its suite of proteomic solutions (Pattern Track™ Process, and ProteinChip® System).
"We are extremely pleased to be partnering with sanofi-aventis, an organization committed to innovation which shares our vision to accelerate and streamline development of new drugs through the early identification of relevant drug efficacy biomarkers," stated Gail S. Page, President and CEO of Ciphergen.
"The partnership allows sanofi-aventis access to our expert scientists and latest technologies and is an important addition to our translational proteomics partnerships for drug discovery and development."
Strong Immune Response in Diseased Corals Potential Trade-OffNews
Researchers have found a correlation between a strong immune response in diseased corals and a lower expression of genes associated with growth and reproduction.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE